Shares of Olema Pharmaceuticals, Inc. (OLMA) are experiencing a dramatic surge in pre-market trading on Tuesday, soaring by an impressive 208.80%. This extraordinary movement comes on the heels of a significant upgrade from a major Wall Street firm.

JPMorgan, a leading investment bank, has raised its price target on Olema Oncology to $32 from $29, while maintaining an Overweight rating on the shares. This bullish stance from JPMorgan appears to be the primary catalyst behind the stock's meteoric rise. The firm's decision to adjust its models and increase the price target suggests growing confidence in Olema's potential in the oncology space.

The pre-market rally in Olema Pharmaceuticals' stock price underscores the significant impact that analyst opinions and price target changes can have on investor sentiment, particularly for biotech companies focused on innovative cancer treatments. As the market opens, investors will be closely watching to see if this momentum can be sustained throughout the regular trading session.